The blood-brain barrier (BBB) strictly regulates the passage of substances into and out of the central nervous system (CNS), playing a crucial role in preventing harmful substances from entering the brain from the bloodstream. However, it also poses a significant challenge by restricting most drugs from reaching the brain parenchyma, severely limiting the treatment of CNS disorders.

Recently, Nanjing RegeneCore has made promising progress in brain-penetrant drug delivery technology, with related pipelines demonstrating potential applications in neurological diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD).

Leveraging high-throughput screening technology, RegeneCore has identified nanobodies capable of effectively crossing the BBB. Furthermore, through advanced antibody engineering and molecular design techniques, these antibody molecules have been extensively optimized, yielding positive results in both in vitro models and murine in vivo studies.

Moving forward, RegeneCore Biotech plans to continue the research, development, and exploration of these drug molecules for their applications in neurological disorders.